ARCHIVES

Secondary AML In High-Dose Chemo Trial Cause For Careful Monitoring, NCI Says

This article is from The Cancer Letter archive.

Vol. 20 No. 33 | August 19, 1994

Download PDF Visit The Full Archive

Related Articles

White House appoints NCI Director Andrew von Eschenbach acting FDA commissioner after Lester Crawford resigns.

September 30, 2005

Longterm Followup Finds Taxotere Improves Survival

January 25, 2008

NCI Advises Five-Year Limit On Tamoxifen Use, in Letter To Doctors

December 8, 1995

New Analyses of PCPT Give Stronger Justification Use of Finasteride To Prevent Prostate Cancer.

May 23, 2008

Cancer Program Critics Called “Irresponsible,” Demagogues”

March 21, 1975

Immunology Grant, Contract Coordination Set; Advice To Applicants-See New Plan

February 8, 1974